AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sortilin

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q99523

UPID:

SORT_HUMAN

Alternative names:

100 kDa NT receptor; Glycoprotein 95; Neurotensin receptor 3

Alternative UPACC:

Q99523; B4DWI3; C0JYZ0; Q8IZ49

Background:

Sortilin, also known as the 100 kDa NT receptor, Glycoprotein 95, or Neurotensin receptor 3, plays a pivotal role in cellular processes. It functions as a sorting receptor in the Golgi compartment and as a clearance receptor on the cell surface. Essential for protein transport from the Golgi to lysosomes and endosomes, Sortilin facilitates the trafficking of lysosomal proteins by binding to them in the Golgi, leading to their transport to prelysosomal compartments. Additionally, it mediates neuronal apoptosis through the endocytosis of proBDNF and proNGFB, acts as a receptor for neurotensin, and is involved in the mineralization of the extracellular matrix and the formation of GLUT4 storage vesicles in adipocytes.

Therapeutic significance:

Understanding the role of Sortilin could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.